First-of-a-kind molecular phenotyping.
Assessing tumor-driving pathway activity.

ISSCR 2019 Congress – visit us at booth #60 | AACR 2019 Congress – visit us at booth #4623

What drives tumor growth?

Built on decades of cell biology research, OncoSignal determines the activity of signal transduction pathways that are involved in cancer to reveal the tumor-driving mechanisms.

Downstream measurement

of RNA molecules enabling quantification of the entire sequence of events of a signaling pathway.

Quantified pathway activity scores

helping to identify aberrant activity and allowing for comparison between tumor samples.

Actionable results

as an aid in identifying therapy targets.

OncoSignal is available for Research Use Only – not for use in diagnostic procedures.

Signaling pathway analysis
Signaling pathway analysis

Signaling pathway analysis

Please view the OncoSignal video to discover the unique features of our solution.

Play
Oncologists & Pathologists
Oncologists & Pathologists
Improving clinical research

Quantitative scores allowing for comparison of tumor samples.

Enabling determination of patient groups based on signaling pathway profiles.

Supporting therapy selection & monitoring

Reference values help identify aberrant pathway activity.

Matching the OncoSignal results with targeted drugs inhibiting signaling pathways may enable selection of the optimal personalized treatment.

OncoSignal pathway analysis in Clinical Research

Retrospective analysis of ER IHC staining positive breast cancer cohort having received adjuvant tamoxifen therapy. OncoSignal was used to assess ER pathway activity in primary tumor samples.

OncoSignal ER pathway analysis

ER pathway activity was elevated in 57% of the patients.

In 43% of the patients ER pathway activity was in the reference tissue range.

OncoSignal pathway activity score indicative for response to endocrine therapy

Disease recurrence was higher in the group with low ER pathway activity, suggesting reduced effectiveness of endocrine therapy in this group.

Multi-pathway analysis may provide direction for alternative therapy

Further analysis of the ER inactive group revealed aberrant activity of other pathways (see PI3K pathway in patient example) relative to reference tissue (grey ranges), suggesting that another therapeutic approach maybe more effective.

Contact us
Cancer researchers
Cancer researchers
OncoSignal in biological research

Determining the tumor-driving mechanisms by measuring the direct output of a signaling pathway.

Studying the direct interaction between drugs and signaling pathways by looking at the molecular phentoype in a cancer cell.

Providing a standardized method for signaling pathway activity measurement.

Click here to download the OncoSignal ‘Validation of signaling pathway models’ poster

OncoSignal in pre-clinical research

Helping to select the best cell lines and PDX models by way of pathway profiling.

Assessing and controlling variability in test systems.

Determining the efficacy of targeted drugs by relating pathway activity to drug response.

OncoSignal pathway analysis in cell cultures

OncoSignal reveals differences in PI3K pathway activity in MCF7 and MDA-MB-231 breast cancer cell lines treated with various drugs (mTOR/AKT/PI3K inhibitors) compared to the vehicle (upper panels). Corresponding cell growth in lower panels.

In the MCF7 cell line with higher initial PI3K activity, drug-induced inhibition of PI3K pathway activity corresponds to inhibition of cell growth. In the MDA-MB-231 cell line with lower initial PI3K activity, drugs are less effective.

OncoSignal pathway analysis in PDX models

Activity of different signaling pathways in PDX models (Charles River Laboratories). Depending on the postulated mode of action of the drug, OncoSignal may help select the PDX model with the optimal pathway activity profile. Based on the activity profiles depicted below, the PDX 713 and 508 models were selected to test PI3K inhibiting drugs.

The two selected PDX models show relatively high PI3K pathway activity in the vehicle group and reduction of pathway activity in the treated groups (data not shown), which coincides with a reduction in tumor growth by various PI3K inhibitors. In the PDX 713 model with the highest PI3K activity in the vehicle group, an almost complete tumor growth inhibition was observed. The PDX 508 model with lower PI3K activity showed less inhibition, stressing the value of OncoSignal testing in the course of your experiment.

For more cancer-type or pathway specific publications, please email us at oncosignal@philips.com.

Now available: OncoSignal service testing

OncoSignal pathway analysis is now available through our dedicated service lab. For more information or a dedicated quotation, please contact the OncoSignal team at oncosignal@philips.com

For Research Use Only – not for use in diagnostic procedures.

Learn more

OncoSignal Service Testing features:

A pathway activity report delivered per sample with quantitative scores of relevant pathways.
Sample types: FFPE or FF human tissues, cell lines, PDX.
Optimized for small sample sizes.
qPCR kits enabling in-house pathway analysis with short turnaround time are in development.
Pathway analysis based on RNAseq data in development.

News & upcoming events

Upcoming events

OncoSignal at events 2019

ISSCR in Amsterdam, NL

February 20-22

Booth #60

AACR in Atlanta, USA

March 29-

April 3
Booth #4623

News

OncoSignal at AACR 2018: OncoSignal tests for pre-clinical research

During the AACR Annual Meeting 2018, we introduced the OncoSignal tests for pre-clinical research. Please view the dedicated flyer for a summary of benefits and supporting data.

Part of these data were generated in collaboration with Charles River Laboratories (CRL). During the AACR Annual Meeting, Anja van de Stolpe (MD and co-inventor of OncoSignal pathway analysis) participated in a Charles River panel to elaborate on the meaning and purpose of signaling pathway analysis in the oncology field (see video). In addition, OncoSignal findings are now accessible through the CRL compendium

Recent publications

• Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model; The American Journal of Pathology, 2018;188:1956-197

• Hedgehog signalling pathway activity in high-grade serous ovarian carcinoma; Poster, EACR 2018

• Determination of signal transduction pathway activity in patient-derived xenograft models in comparison with clinical patient tumor samples for a variety of human cancer types; Poster, AACR 2018

• Measuring functional signal transduction pathway activity on breast cancer tissue samples to determine intra-tumor heterogeneity and heterogeneity between primary and metastatic tumors; Poster, AACR 2018

• Targeted disruption of transcriptional effector GLI2 attenuates breast tumor growth and metastatis; Poster, SABCS 2017

For more cancer-type or pathway specific publications, please email us at oncosignal@philips.com

Contact information

* This field is mandatory

Country

First name*

First name (phonetic)

Last name*

Last name (phonetic)

Salutation

Academic title

Email address*

Business phone

Company*

Job title

Industry

Function

Specialty

Department

State or Province

City

Address

Zip or Postal Code

By specifying your reason for contact we will be able to provide you with a better service.

Follow up information

Preferred method of contact

Best time to call

Estimated time of purchase

Comments

What is cross border data transfer?

I agree on cross-border transfer of personal information.

I would like to receive marketing related electronic communications about Philips products, services, events and promotions that may be relevant to me based on my user preferences and behaviour.

First-of-a-kind molecular phenotyping. Assessing tumor-driving pathway activity.

ISSCR 2019 Congress – visit us at booth #60 | AACR 2019 Congress – visit us at booth #4623

What drives tumor growth?

Downstream measurement

Quantified pathway activity scores

Actionable results

Signaling pathway analysis

Improving clinical research

Supporting therapy selection & monitoring

OncoSignal pathway analysis in Clinical Research

OncoSignal ER pathway analysis

OncoSignal pathway activity score indicative for response to endocrine therapy

Multi-pathway analysis may provide direction for alternative therapy

OncoSignal in biological research

OncoSignal in pre-clinical research

OncoSignal pathway analysis in cell cultures

OncoSignal pathway analysis in PDX models